QIAGEN and Applied Biosystems Settle all Disputes over Real-Time PCR Thermal Cycler Patents
News Jan 23, 2009
QIAGEN and Applied Biosystems have announced a settlement of their disputes concerning infringement by Corbett’s Rotor-Gene™ Real-Time PCR-Cyclers and Applied Biosystems’ Real-Time Thermal Cycler Instrument patents.
Applied Biosystems had filed an infringement lawsuit against Corbett in Germany and Corbett later filed a declaratory judgment lawsuit in California. Further, Corbett and ltf Labortechnik filed an intervention in opposition proceedings before the European Patent Office. QIAGEN acquired Corbett, an Australian instrumentation manufacturing company, in July 2008.
In connection with the settlement, Corbett has entered into an agreement with Applied Biosystems to take a license to certain technology relating to Corbett’s Real-Time PCR-Instrumentation and its use. The license covers all fields including research-related fields, applied fields and the fields of human and animal in vitro diagnostics.
Financial terms of the settlement and related license agreement were not disclosed. These agreements fully resolve all pending disputes between Corbett, QIAGEN, ltf Labortechnik, and Applied Biosystems.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.